Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Study Details
Study Description
Brief Summary
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
|
Detailed Description
PRIMARY OBJECTIVES:
-
Demonstrate ability to monitor cancer-specific deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteomic alterations from plasma.
-
Improve detection of recurrences post completion of curative therapies through monitoring of plasma cancer-specific DNA, RNA and proteomic alterations.
SECONDARY OBJECTIVES:
-
Qualitative and quantitative changes in cancer-specific plasma alterations during neoadjuvant, adjuvant therapies and surveillance.
-
Disease free survival (DFS) of patients with detectable cancer-specific plasma alterations.
-
Overall survival (OS) of patients with detectable cancer-specific plasma alterations.
EXPLORATORY OBJECTIVES:
-
Optimal combination of cancer-specific plasma DNA, RNA and / or proteomic alterations for early detection of recurrences.
-
Sensitivity, specificity, positive predictive and negative predictive values of cancer-specific plasma alterations in detecting recurrences.
-
Correlation between cancer-specific alterations in plasma and tissue and either with outcomes including DFS & OS.
-
Nature and frequency of detection of incidental non-colorectal cancer related DNA, RNA and / or proteomic alterations.
OUTLINE:
Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients' medical records may also be reviewed.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Ancillary-correlative (biospecimen collection) Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed. |
Procedure: Biospecimen Collection
Undergo collection of blood and tissue samples
Other: Electronic Health Record Review
Review of medical records
|
Outcome Measures
Primary Outcome Measures
- Analysis of deoxyribonucleic (DNA), ribonucleic acid (RNA), and proteomic alterations from plasma [Up to 5 years]
To detect circulating tumor DNA (ctDNA) in plasma samples from patients with colorectal cancer (CRC) who have completed curative therapies (i.e. minimal residual disease) towards predicting recurrence earlier than the current standard of care utilizing the CRC23 assay and the LUNAR assay from Guardant Health technology.
- Detection of recurrences post completion of curative therapies [Up to 5 years]
To detect ctDNA in plasma samples from patients with CRC who have completed curative therapies (i.e. minimal residual disease) towards predicting recurrence earlier than the current standard of care utilizing the CRC23 assay and the LUNAR assay from Guardant Health technology.
Secondary Outcome Measures
- Changes in cancer-specific plasma alterations during neoadjuvant, adjuvant therapies and surveillance [Baseline up to 5 years]
Will assess the association between changes in circulating molecules and response in patients undergoing neoadjuvant therapy by linear or logistic regression models
- Disease free survival (DFS) [Up to 5 years]
- Overall survival (OS) [Up to 5 years]
Other Outcome Measures
- Optimal combination of cancer-specific plasma DNA, RNA and / or proteomic alterations for early detection of recurrences [Up to 5 years]
- Sensitivity, specificity, positive predictive and negative predictive values of cancer-specific plasma alterations in detecting recurrences [Up to 5 years]
- Correlation between cancer-specific alterations in plasma and tissue and either with outcomes including DFS & OS [Up to 5 years]
- Nature and frequency of detection of incidental non-colorectal cancer related DNA, RNA and / or proteomic alterations [Up to 5 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years.
-
Histological/cytological confirmation of colorectal adenocarcinoma.
-
Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
-
Ability to understand and the willingness to sign a written informed consent document.
-
Willing to pursue standard of care surveillance post completion of curative therapies.
-
Willing to provide blood samples for correlative research.
Exclusion Criteria:
-
Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
-
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Banner - MD Anderson Cancer Center | Gilbert | Arizona | United States | 85234 |
2 | Baptist- MD Anderson Cancer Center | Jacksonville | Florida | United States | 32207 |
3 | The Queen's Medical Center | Honolulu | Hawaii | United States | 96813 |
4 | St. Luke's Cancer Institute | Boise | Idaho | United States | 83712 |
5 | Cooper Hospital UNIV MED CTR. | Camden | New Jersey | United States | 08103 |
6 | Houston Methodist Cancer Center | Houston | Texas | United States | 77030 |
7 | M D Anderson Cancer Center | Houston | Texas | United States | 77030 |
8 | UT Health San Antonio MD Anderson Cancer Center | San Antonio | Texas | United States | 78229 |
9 | Baylor Scott & White Research Institute | Temple | Texas | United States | 76508 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
Investigators
- Principal Investigator: Arvind Dasari, M.D. Anderson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- PA18-1171
- NCI-2020-10034
- PA18-1171